EE653 Cost-Effectiveness of Adjuvant Olaparib for Patients With Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Breast Cancer in Portugal
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.933
https://www.valueinhealthjournal.com/article/S1098-3015(24)03796-3/fulltext
Title :
EE653 Cost-Effectiveness of Adjuvant Olaparib for Patients With Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Breast Cancer in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03796-3&doi=10.1016/j.jval.2024.10.933
First page :
Section Title :
Open access? :
No
Section Order :
10428